Biotricity (BTCY) Q3 2026 earnings summary

Executive summary

• Achieved third consecutive quarter of positive net operating income and EBITDA, reflecting disciplined execution, operational efficiency, and recurring technology fees and device sales growth.

• Rapid expansion of digital ecosystem, with app users growing from 4,500 to over 44,000 in two years and a provider network supporting up to 4 million patients annually.

• High customer retention rate exceeding 90%, driven by solution quality and customer support.

• Demand for remote patient management and chronic cardiac care solutions continues to accelerate, driven by an aging population and healthcare staffing shortages.

• Strategic initiatives and technological advancements, including AI-enabled solutions, position the company for sustained growth and profitability in 2026.

Financial highlights

• Revenue for Q3 FY2026 increased 10.2% year-over-year to $4 million, and $11.7 million for the nine months ended December 31, 2025, up 16.5% year-over-year.

• Gross margin improved to 81.5% for Q3 FY26, and 81.3% for the nine months, up from 76.4% and 75.2% respectively.

• Operating expenses decreased 4.2% to $2.8 million for the quarter, and 6.8% to $8.55 million for the nine months, with SG&A down and R&D up.

• Net loss attributable to common stockholders narrowed to $1.1 million ($0.042 per share) for the quarter, and $2.08 million for the nine months.

• Free cash flow positive for six consecutive quarters, with $1.8 million generated for the nine months.

Outlook and guidance

• Expects continued strong adoption of Biotres Pro and further top-line revenue growth in 2026, with ongoing investment in R&D and commercialization of new products.

• Anticipates achieving net income profitability within the year, building on current positive trends.

• Focus remains on U.S. market expansion, with opportunistic international growth through distribution partnerships and regulatory approvals.

• Company expects existing cash and anticipated near-term financings to meet needs for the next twelve months, but additional capital may be required for further expansion.